Opinion|Videos|November 13, 2025
Subgroup Analysis of Patients With No Prior Chemotherapy in EMERALD Trial
Among chemotherapy-naive patients, elacestrant extended median progression-free survival compared with standard therapy, particularly in ESR1-mutated cases.
Advertisement
Episodes in this series
A focused analysis of chemotherapy-naive patients revealed elacestrant’s superior efficacy, demonstrating a median PFS of 3.7 months vs 2.0 months for standard of care in all patients. Among those with ESR1-mutated tumors, elacestrant extended median progression-free survival to 5.3 months vs 1.9 months for standard of care. These findings highlight elacestrant’s particular benefit in patients who have not yet received chemotherapy.
Advertisement
Related to this article
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
Why consumers still can’t comparison shop for medication
3
The hidden costs of routine radiology and how they can be addressed
4
When the referral isn't the finish line: Making SDOH programs actually close care gaps
5